Lonza and Touchlight collaborate on end-to-end mRNA offering
Lonza Group AG
/ Key word(s): Partnership
Basel, Switzerland and Hampton, UK, 6 September 2022 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced a collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution. Through this collaboration, Lonza will have the ability to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA (mRNA) therapeutics and vaccines, while Touchlight can widen the channels through which customers can gain access to its novel doggybone DNA (dbDNA) technology.
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process which enables GMP production at unprecedented speed, scale and purity. Access to this technology expands the options for Lonza’s customers beyond the traditional method of working with plasmid DNA (pDNA), while continuing to benefit from the company’s integrated mRNA manufacturing offering.
André Goerke, Vice President, Business Unit Head mRNA, Lonza, commented: “The strategic collaboration with Touchlight enables Lonza to further enhance its position as a global leader in mRNA manufacturing. We can now provide our customers with a strong foundation to deliver an end-to-end offering that includes access to a novel synthetic DNA technology. Such an integrated solution can prove beneficial in speeding up time to market, which is critical in the fast-paced industry of mRNA manufacturing.”
Karen Fallen, CEO, Touchlight DNA Services, added: “We are delighted to provide Touchlight customers the benefits of an end-to-end mRNA offering through our collaboration with Lonza. Lonza is the leading CDMO in mRNA manufacturing and has an established, global mRNA manufacturing network. The alliance allows both companies to innovate and to extend their offering on a global level.”
DNA serves as the starting template for the production of mRNA. Through an enzymatic in-vitro transcription process, this DNA sequence is then transcribed into a single-stranded RNA molecule, which is then processed into mRNA. Current mRNA-based therapeutics in development include vaccines for infectious diseases and immuno-oncology.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com
Lonza Contact Details
Touchlight Contact Details
Agnes Stephens / Tim Watson
End of Media Release
|Company:||Lonza Group AG|
|Phone:||+4161 316 81 11|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1435981|
|End of News||EQS News Service|